Automating Infectious Disease Biologics Prior Auth for Critical Therapies

Navigating the complexities of infectious disease biologics prior auth demands precision and speed. Klivira streamlines this critical process, ensuring timely access to high-cost specialty medications.

For infectious disease clinics and health systems, managing prior authorizations for biologics and other high-cost specialty drugs presents a significant operational burden. From complex indication-specific criteria to frequent re-authorizations, manual workflows can delay patient care and strain revenue cycles. Klivira addresses these challenges by automating key steps in the infectious disease biologics prior auth journey.

Navigating Biologics Prior Auth for Infectious Disease Patients

While biologics are predominantly used in specialties like rheumatology or gastroenterology, infectious disease patients often require these advanced therapies for co-morbid conditions or, in some cases, for specific immunomodulatory or antiviral applications. Managing prior authorizations for these high-cost agents, alongside typical ID PA categories like antivirals (HCV, HIV), antifungals, and OPAT, adds significant complexity to the revenue cycle.

Key Prior Authorization Triggers for Biologics in Infectious Disease

High-cost specialty biologics (e.g., monoclonal antibodies, immunomodulators)
Indication-specific criteria for concomitant conditions (e.g., IBD, psoriasis in an ID patient)
Step therapy requirements, including biosimilar mandates per payer policy
Mandatory pre-screening (e.g., TB, Hepatitis B/C) for immunosuppressive therapies
Periodic re-authorization for chronic biologic treatment regimens
Medical vs. pharmacy benefit routing based on administration mode

Klivira's Automated Workflow for Infectious Disease Biologics Prior Auth

Klivira automates critical steps in the infectious disease biologics prior authorization process, integrating directly with EMRs to pull necessary clinical data. This includes identifying the specialty and disease state, applying payer-specific step therapy logic, and streamlining documentation for required screenings. Our platform ensures that the unique considerations of ID patients receiving biologics are addressed efficiently, reducing manual effort and accelerating approvals.

Optimizing EMR and Payer Touchpoints for ID Biologics

**EMR Integration:** Extracting diagnoses (e.g., ICD-10 for HIV, Hepatitis), lab results (TB, Hepatitis serologies), and medication histories from EMR systems via SMART on FHIR.
**Order Types:** Processing specialty medication orders from infectious disease providers, including those for biologics.
**Payer Channels:** Submitting X12 278 transactions, ePA via NCPDP SCRIPT, and navigating payer-specific portals for biologics.
**Clinical Templates:** Utilizing structured data from infectious disease-specific EMR templates to support medical necessity.
**Benefit Verification:** Routing requests correctly based on medical vs. pharmacy benefit, often critical for infused biologics.

Evidence-Based Prior Authorization and Compliance Considerations

Prior authorization for biologics in infectious disease settings often aligns with established clinical guidelines from bodies like the Infectious Diseases Society of America (IDSA) or payer-specific medical policies. Klivira's platform incorporates logic to support these evidence-based criteria, facilitating quicker approvals. Organizations should also consider discussing HIPAA and ePHI management with their compliance teams, especially when exchanging sensitive patient data for these complex cases.

Frequently asked questions

How does Klivira handle the specific screening requirements for biologics in ID patients?

Klivira integrates with your EMR to automatically extract relevant screening results, such as TB (PPD or IGRA) and Hepatitis B/C serologies. This data is then structured and submitted with the prior authorization request, ensuring compliance with payer and clinical guidelines for immunosuppressive therapies.

Can Klivira manage prior authorizations for both traditional ID drugs and biologics?

Yes, Klivira's platform is designed to manage prior authorizations across a broad spectrum of medications. This includes high-cost antivirals (e.g., for HCV, HIV), antifungals, OPAT regimens, and the complex requirements for biologics, whether used for primary ID indications or co-morbid conditions.

How does Klivira manage re-authorizations for chronic biologic therapies?

For chronic biologic treatments, Klivira automates the re-authorization process by tracking typical 6 or 12-month cycles. The system prompts for updated clinical documentation, such as disease activity or response to therapy, directly from the EMR, streamlining subsequent submissions.

What EMR systems does Klivira integrate with for infectious disease prior auth?

Klivira integrates with leading EMR systems using industry standards like SMART on FHIR. This allows for seamless data exchange to support prior authorization workflows for infectious disease patients, including those requiring biologics. Specific integration capabilities can be discussed with our technical team.

Does Klivira support biosimilar substitution requirements for biologics?

Yes, Klivira's workflow incorporates payer-specific biosimilar substitution policies. The system helps identify and route requests according to mandates that require specific biosimilars to be tried first, ensuring adherence to policy and reducing potential denials.